Omomyc, a MYC mutant that has been delivered as transgene in cell lines, and as miniprotein in preclinical tumor models, has been shown to block proliferation and induce apoptosis of cancer cells specifically, leading to immune cell infiltration [28], and might represent an attractive target for HNSCC therapy. The gene discussed is MYC; the disease is head and neck squamous cell carcinoma.